

# University Health Network

## **Economics, Ethics and Muda:**

### **A New Appreciation for Ontario's Health Care System and Academic Health Sciences Centres?**


**Dr. Bob Bell, President & CEO**

**Breakfast with the Chiefs**

**October 19, 2005**

# Health care Spending in Canada

Close



**“What’s Good for General Motors is Good for America”**  
**-Charles Wilson, GM Chairman, 1955 Senate hearings**



GM Assembly Plant, Flint Mi., 1956

# GM Assembly Plant, Flint Mi., 2001



# What Ails GM?

By George F. Will, Washington Post (May 1, 2005)

“And the cost of providing health coverage for 1.1 million GM workers, retirees and dependents is estimated to be \$5.6 billion this year. Their coverage is enviable -- at most, small co-payments for visits to doctors and for pharmaceuticals but no deductibles or monthly premiums. GM says health expenditures -- \$1,525 per car produced; there is more health care than steel in a GM vehicle's price tag -- are one of the main reasons it lost \$1.1 billion in the first quarter of 2005. Ford's profits fell 38 percent, and although Ford had forecast 2005 profits of \$1.4 billion to \$1.7 billion, it now probably will have a year's loss of \$100 million to \$200 million.”

# WOODSTOCK LANDS TOYOTA PLANT –

## Just the Beginning

As many as 9,000 spin-off jobs are expected from the huge undertaking, backed by \$125 million in government money




Today's Economy

# Toronto Medical Discovery Tower- The Economy of the Future?



# New Drugs



# The Image-Guided Therapy (IGTx) Group

Ontario Cancer Institute, Princess Margaret Hospital, University Health Network

Departments of Radiation Physics, Radiation Medicine Program

Departments of Radiation Oncology, Medical Biophysics, University of Toronto


IGTx

## Principal Investigators

- Dr. David A. Jaffray, Head, Radiation Physics
- Dr. Jeffrey H. Siewerdsen, Scientist, OCl

## About IGTx

## Contact Information



# Ontario Health care System

- **Our brand - an asset, not a liability**
- **Makes Ontario's economy competitive today**
- **Educated, mobile and healthy workforce**
- **Health science centers offer good jobs today & may offer tomorrow's economic drivers**

# TIME

THERE IS NEW **AMMUNITION**  
IN THE WAR AGAINST

# CANCER.

**THESE ARE THE BULLETS.**


Revolutionary new pills like **GLEEVEC** combat cancer by targeting only the diseased cells. Is this the breakthrough we've been waiting for?




# Targeted Therapy

## Gleevec: HOW IT WORKS

without  
Gleevec®




with  
Gleevec®



Leukemia

## Molecular Therapeutics




Sarcoma

# Sarcoma Response to Gleevec




## STI- Responder



**baseline**




**+ 8 weeks**



**+ 6  
months**

# Sarcoma Response to Gleevec



# Proof of Principles


- Dissimilar cancers have common features
- Therapy targeted to molecular alterations is possible
- Cancer as chronic disease
- How do we assess cost of treatment?



# Incremental Cost/QALY Gained

- Difference in cost
- Divided by difference in QALY
- $(\Delta \text{cost} / \Delta \text{QALY})$
- $\Delta \text{QALY} = \text{difference in years of life} \times \text{difference in health status}$

1.2000000179  
1.0000000149  
0.8000000119  
0.6000000089  
0.4000000060  
0.2000000030  
0



# Relative Benefit (NICE)

**Table 4. Cost per QALY league table<sup>1</sup>**

Intervention	Extra cost per QALY gained (1990 £)
GP advice to stop smoking	270
Hip replacement	1,180
Cholesterol testing and treatment (all adults aged 40–69)	1,480
Kidney transplantation (cadaver)	4,710
Home haemodialysis	17,260
Hospital haemodialysis	21,970
Erythropoietin treatment for anaemia in dialysis patients (assuming 10% reduction in mortality)	54,380
Neurosurgery for malignant intracranial tumours	197,780

# Level of Evidence Underlying Calculations


Evidence quality	Cost per QALY gained (£)			
	<£5K	£5-20K	>£20K	Negative
I. At least one randomised controlled trial	Strongly recommended	Strongly recommended	Limited support	Not supported
II. Well designed controlled trial	Strongly recommended	Supported	Limited support	Not supported
III. Expert consensus or opinion	Supported	Limited support	Limited support	Not supported
IV. Conflicting or inadequate evidence	Not proven	Not proven	Not proven	Not supported

# Gleevec in GIST

- Incremental Cost- \$45,000/year
- Incremental life years- 3
- Improvement Quality of Life- (.25 → 1.0)
- Incremental Cost /  $\Delta$  QALY =  $45/4 = \$11,250/$   
QALY

# Avastin - New Drug Starves Tumor Blood Supply

## How **Avastin** Starves a Tumor



Tumors need blood, and they have a devious way to get it:

>> They secrete a protein called **VEGF** that docks with receptors in nearby blood vessels, stimulating the growth of new blood vessels.

>> Genentech foils this plot with **Avastin**, a drug that binds with VEGF and prevents that protein from attaching to receptors. New blood vessels don't form, and the tumor starves.

# Avastin

- Approved for use in advanced colorectal cancer in September 2005
- Likely to cost at least \$60,000 more per patient when compared to 5FU
- Survival advantage 5 months
- Assuming no degradation of quality of life - Avastin cost/QALY =  $12/5 \times 60,000 = \$144,000/\text{QALY}$

## Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial – Roy A Patchell et al (Lancet 2005)

- Comparison of radiation (\$3K) vs. surgery and radiation (\$57K) for Rx of acute spinal mets- 27% improvement in walking
- Assume paraplegia = 0, walking =1, relative improvement in quality = .27
- However, life expectancy of entire group = 5/12- therefore, QALY =  $.27 \times 5/12 = .1$
- Cost per QALY =  $\$54 \text{ K} / .1 = \$540,000/\text{QALY}$

# Cost Effectiveness of Limb Salvage

- No data on change in health status
- No improvement survival
- Acute costs-  
Amputation (\$1.5K)  
vs LS (\$20K)
- Chronic costs- (\$3K/  
prosthesis)



SEPTEMBER 5, 2005

www.time.com AOL Keyword: TIME

CHINESE CYBERSPIES  
COOL NEW SEARCH ENGINES

TIME



HOW TO  
STOP A  
**HEART  
ATTACK**  
BEFORE IT  
HAPPENS

Amazingly detailed new  
**HEART SCANS** help doctors  
spot trouble without  
surgery. How technology  
could save your life



Mike Fackelmann, 50,  
holds a scan of his  
heart, which revealed  
a major blockage of a  
coronary artery (arrow)

# Cardiac Imaging



# Resource Allocation & Priority Setting

- **Linda Wright** MHS<sub>c</sub>, MSW, RSW  
**Eoin Connolly**, MA



# Ethical Issues

- We have a duty to care for all patients
- Need to treat all patients fairly
- Ethical challenge = To find a *fair* way to make tough decisions about scarce resources

# Ethical Framework:

## Goals are legitimacy and fairness

- **Legitimacy:** who has moral authority to make priority setting decisions about available resources?
- **Fairness:** when does a stakeholder have sufficient reason to accept a priority setting decision as fair?



# Ethical Framework:

## Accountability for reasonableness (A4R)

- **Relevance** – decisions based on reasons fair-minded people can agree are relevant under the circumstances
- **Publicity** – reasons publicly accessible
- **Revision** – opportunities to revisit/revise decisions & mechanism to resolve disputes
- **Empowerment** – optimise effective participation and minimise power differences
- **Enforcement** – to ensure 4 conditions met

# A4R in action: Key elements

- Relevance



- Publicity

- Revision

- Empowerment

- Enforcement



**PROCESSES**

# Criteria

- Strategic fit
- Alignment with external directives
- Academic mandate
  - Education
  - Research
- Clinical impact
- Community needs
- Partnerships (external)
- Resource implications- cost effectiveness

(Gibson, Martin & Singer. 2004. "Priority setting in health care organisations: criteria, processes, & parameters of success." *BMC Health Services Research* 4:25.)

# Process Elements

- **Ensure strategic alignment**
- **Identify decision-makers**
- **Define criteria Collect data/information**
- **Engage internal/external stakeholders**
- **Develop an effective communication plan**
- **Communicate decision & its rationale**
- **Develop decision review processes**
- **Monitor/evaluate & improve**
- **Lead by example**

Daniels & Sabin. 2002. *Setting limits fairly: can we learn to share scarce resources?* Oxford University Press. Gibson, Martin & Singer. 2005. Priority setting in hospitals: fairness, inclusiveness, and institutional power differences. *Social Science & Medicine* (in press)

# Benefits of approach

- Board: due diligence, accountability
- Senior management: strategic operations, quality improvement, learning organization
- Staff: EBMx, political engagement
- Patients: fair treatment
- Community: sense of involvement
- Other health care organizations: shared lessons, system improvement
- Government: accountability

# What happens if treatment does not meet the cost-effectiveness hurdle?

- Ignore
- Treatment in America?
- Treatment in “private” Canadian centers?
- “Private” treatment in public facilities?



# Ethics, TPS & Muda

- Toyota is one of only two auto companies making money on cars
- Taiichi Ohno- father of TPS
- Institute for Healthcare Improvement- Berwick and Spear
- Lean techniques (elimination of muda) in health care



# Principles of TPS- Elimination of Muda

- **Standardize processes**
- **Pull, not push efficiency**
- **Efficiency pull comes from developing people**
- **Eliminate work that does not add value**

# 100k *lives* Campaign

SOME IS NOT A NUMBER. SOON IS NOT A TIME.

# **Standardization - Six Changes That Save Lives**

- 1. Deploy Rapid Response Teams**
- 2. Deliver Reliable, Evidence-Based Care for Acute Myocardial Infarction**
- 3. Prevent Adverse Drug Events (ADEs)**
- 4. Prevent Central Line Infections**
- 5. Prevent Surgical Site Infections**
- 6. Prevent Ventilator-Associated Pneumonia**

# Three Sources of Muda in Health Care System

- **Wrong level of care**
- **Difficult processes**
- **Inappropriate resource utilization**


# Right Patient - Right Bed

- **Criteria for CC admission**
- **Criteria for acute care setting**
- **Criteria for community care**



# Processes

- ED overcrowding has little to do with ED
- Bottlenecks
- Scheduling
- Resources
- Processes around ED have major impact on ED waits



# Resource Utilization

- The people who determine resource utilization are not our employees
- How do we get physicians to consider resources in therapeutic decision making?



# Summary

- **Health care is a critical economic asset**
- **We will face increasing complexity in deciding what services are funded**
- **We need an ethical framework for decision making**
- **We need to ensure that we are constantly examining opportunities for improving our systems and developing tools to measure efficiency**

Questions or Comments?